Biologics for Psoriasis - 23/05/24
Résumé |
Biologic therapies targeting tumor necrosis factor alpha (TNF-α) (infliximab, adalimumab, certolizumab, etanercept), the p40 subunit shared by IL-12 and IL-23 (ustekinumab), the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab), IL-17A (secukinumab, ixekizumab), IL-17-RA (brodalumab) and both IL-17A and IL-17F (bimekizumab) have revolutionized the treatment of psoriasis. In both the short and long term, risankizumab had highest Psoriasis Area and Severity Index 90 scores compared to other oral and injectable biologics. IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most favorable long-term risk-benefit profile compared to IL-17, IL-12/23, and TNF-α inhibitors.
Le texte complet de cet article est disponible en PDF.Keywords : Psoriasis, Biologics, Efficacy, Safety
Plan
| Funding Sources: G.F. Chen was supported by a Yale School of Medicine Medical Student Research Fellowship. A.M. Wride and S.L. Spaulding were supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, United States under Award Number T35DK104689. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
Vol 42 - N° 3
P. 339-355 - juillet 2024 Retour au numéro
Article précédent
- Psoriasis in 2024 and Beyond
- Jeffrey M. Cohen
- Oral Psoriasis Therapies
- JaBreia James, Tracey Otto, Julia Gao, Martina L. Porter
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?